Prothena Corporation plc (PRTA) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

My name is Pam, and I will be your coordinator for today. At this time, all participants are in listen-only mode. We will be facilitating a question and answer session towards the end of today's call. If at any time during the call you require assistance, please press star, followed by zero, and a coordinator will be happy to assist you. I would now like to turn the call over to Mark Johnson, Vice President at Prisina. Please proceed. Thank you. Good afternoon, everyone, and welcome to today's call to review Procena's business progress, fourth quarter and full year 2024 financial results, and 2025 financial guidance. Please review the press release we issued earlier today, which is available on our website at procena.com and is also attached to a Form 8-K filed today with the SEC. In addition, we are using supplemental slides, which are available on the Invent and Presentation section of our Investor Relations website. On today's call, Dr. Jean Kenney, our President and Chief Executive Officer, will provide opening remarks, including an overview of Prothena's corporate and development strategy. Chad Swanson, our Chief Development Officer, will provide an update on our ongoing wholly owned clinical program. And Brandon Smith, our Chief Operating Officer, will provide commercial insights on those programs. Tron Nguyen. Our Chief Financial Officer and Chief Strategy Officer will then discuss our 2024 financial results and 2025 financial guidance before turning it back to Jean for closing remarks, at which point we will open up the call for a Q&A session. Before we begin, I would like to remind you that during today's presentation, we will be making forward-looking statements that are subject to certain risks, uncertainties, and other factors that could cause actual resu...